The genome of PD-L1 was disrupted for significantly the augmented efficacy of immune checkpoint blockade therapy to increase the infiltration of T cells into tumor sites for reprogramming an immunosuppressive tumor condition into an immunoactive microenvironment (Figure 4c). This evidence concerns the gene CD274 and neoplasm.